- Home
- MFA vs COLL Comparison
MFA vs COLL Comparison
Compare MFA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- COLL
- Stock Information
- Founded
- MFA 1997
- COLL 2002
- Country
- MFA United States
- COLL United States
- Employees
- MFA N/A
- COLL N/A
- Industry
- MFA Real Estate Investment Trusts
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- COLL Health Care
- Exchange
- MFA Nasdaq
- COLL Nasdaq
- Market Cap
- MFA 1.1B
- COLL 1.0B
- IPO Year
- MFA N/A
- COLL 2015
- Fundamental
- Price
- MFA $10.60
- COLL $30.93
- Analyst Decision
- MFA Buy
- COLL Strong Buy
- Analyst Count
- MFA 5
- COLL 5
- Target Price
- MFA $13.50
- COLL $43.60
- AVG Volume (30 Days)
- MFA 929.4K
- COLL 441.9K
- Earning Date
- MFA 02-19-2025
- COLL 02-20-2025
- Dividend Yield
- MFA 13.26%
- COLL N/A
- EPS Growth
- MFA N/A
- COLL 757.11
- EPS
- MFA 1.60
- COLL 2.16
- Revenue
- MFA $366,192,000.00
- COLL $599,245,000.00
- Revenue This Year
- MFA N/A
- COLL $13.25
- Revenue Next Year
- MFA $14.93
- COLL $18.14
- P/E Ratio
- MFA $6.60
- COLL $14.24
- Revenue Growth
- MFA 164.50
- COLL 9.62
- 52 Week Low
- MFA $9.36
- COLL $28.39
- 52 Week High
- MFA $13.45
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- MFA 56.59
- COLL 45.90
- Support Level
- MFA $10.06
- COLL $32.28
- Resistance Level
- MFA $10.57
- COLL $33.45
- Average True Range (ATR)
- MFA 0.19
- COLL 1.07
- MACD
- MFA 0.08
- COLL -0.16
- Stochastic Oscillator
- MFA 92.91
- COLL 2.05
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company is an internally managed real estate investment trust or REIT.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.